You just read:

RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

News provided by

RXi Pharmaceuticals Corporation

Jun 21, 2017, 07:05 ET